ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 159.8 USD | -2.28% |
|
-5.62% | +3.32% |
| 04-29 | Health Care Up on Growth Optimism -- Health Care Roundup | DJ |
| 04-29 | BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating | MT |
| Sales 2024 * | 55.07B 4,385B | Sales 2025 * | 57.92B 4,612B | Capitalization | 283B 22,502B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.18B 651B | Net income 2025 * | 11.03B 878B | EV / Sales 2024 * | 6.1 x |
| Net Debt 2024 * | 53.1B 4,228B | Net Debt 2025 * | 46.7B 3,718B | EV / Sales 2025 * | 5.69 x |
| P/E ratio 2024 * |
30.5
x | P/E ratio 2025 * |
23.7
x | Employees | 50,000 |
| Yield 2024 * |
3.88% | Yield 2025 * |
4.07% | Free-Float | 96.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
| 1 day | -2.28% | ||
| 1 week | -5.62% | ||
| Current month | -11.93% | ||
| 1 month | -11.93% | ||
| 3 months | -2.69% | ||
| 6 months | +16.78% | ||
| Current year | +3.32% |
1 week
157.77
171.30
1 month
157.77181.43
Current year
154.54182.72
1 year
130.98182.72
3 years
105.59182.72
5 years
56.90182.72
10 years
37.21182.72
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 31/12/12 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 31/12/12 |
Robert Michael
PSD | President | 53 | 31/12/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 31/12/12 |
Edward Rapp
BRD | Director/Board Member | 66 | 31/12/12 |
| Director/Board Member | 70 | 31/12/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 159.5 | +0.28% | 99,442 |
| 26/04/24 | 159.1 | -4.92% | 102,502 |
| 25/04/24 | 167.3 | -0.52% | 3,211 |
| 24/04/24 | 168.2 | -1.15% | 206,873 |
| 23/04/24 | 170.1 | +0.50% | 738,782 |
Delayed Quote London S.E., April 29, 2024 at 04:30 pm
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
03/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
159.6
USD
Average target price
182.6
USD
Spread / Average Target
+14.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B | |
| -10.94% | 144B |
- Stock Market
- Equities
- ABBV Stock
- 0QCV Stock
